CD11/CD18 and CD14 share a common lipid A signaling pathway

Area of Science:

• Immunology
• Cell Biology
• Microbiology

Background:

• Lipid A, the active component of lipopolysaccharide (LPS), triggers phagocyte activation, contributing to Gram-negative sepsis pathogenesis.
• CD14 and CD11/CD18 are known LPS receptors, but the LPS signal transduction cascade remains unclear.
• CD14 lacks intracellular signaling domains, implying a need for an associated molecule for cell activation.

Purpose of the Study:

• To investigate similarities in signaling pathways utilized by CD14 and CD11/CD18 in response to LPS.
• To identify the specific receptor responsible for discriminating between LPS and its antagonists.
• To elucidate the true signal transducer in LPS-induced cellular activation.

Main Methods:

• Transfection of Chinese hamster ovary (CHO)-K1 cells with CD14 and CD11/CD18.
• Assessing LPS-induced cellular activation and bacterial binding in transfected cells.
• Analyzing the agonist/antagonist activity of synthetic lipid A analogues.

Main Results:

• LPS-binding protein enhanced LPS-induced activation and bacterial binding in CD11/CD18-transfected cells, suggesting it interacts with CD11/CD18.
• Synthetic lipid A analogues exhibited identical agonist/antagonist effects irrespective of the expressed LPS receptor (CD14 or CD11/CD18).
• These findings support a model where a distinct receptor mediates LPS signal transduction.

Conclusions:

• A receptor separate from CD14 and CD11/CD18 is hypothesized to be the primary signal transducer for LPS-induced cellular activation.
• This distinct receptor is responsible for differentiating between LPS lipid A and potential antagonists.
• Understanding this true signal transducer could offer new therapeutic targets for Gram-negative sepsis.